Exelixis to Presents Results of Cabometyx (cabozantinib) in P-II Trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

Published: May 27, 2022 | Tags: Exelixis, Cabometyx, cabozantinib, P-II Trial, Head, Neck, Squamous Cell Carcinoma, ASCO, 2022

ManaMed’s ManaSport Ultrasound Therapy Class II Device Receives the US FDA’s Approval for the Treatment of Chronic Pain

Published: May 27, 2022 | Tags: ManaMed, ManaSport, Ultrasound Therapy Class II Device, US, FDA, Approval, Chronic Pain

AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for UC & CD in The Lancet

Published: May 27, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, Skyrizi, risankizumab, P-III, Induction, Maintenance Studies, UC & CD

BMS to Present Results of Breyanzi (lisocabtagene maraleucel) in P-II (PILOT) Study for R/R Large B-cell Lymphoma at ASCO 2022

Published: May 27, 2022 | Tags: BMS, Breyanzi, lisocabtagene maraleucel, P-II, PILOT Study, Large B-cell Lymphoma, ASCO, 2022

Pfizer’s Ervogastat + Clesacostat Receives the US FDA’s Fast Track Designation for the Treatment of Non-Alcoholic Steatohepatitis

Published: May 27, 2022 | Tags: Pfizer, Ervogastat, Clesacostat, US, FDA, Fast Track Designation, Non-Alcoholic Steatohepatitis

Takeda and Seagen to Present Results of Adcetris (brentuximab vedotin) for the Treatment of Advanced Hodgkin Lymphoma at ASCO 2022

Published: May 27, 2022 | Tags: Takeda, Seagen, Adcetris, brentuximab vedotin, Hodgkin Lymphoma, ASCO, 2022

Legend’s Carvykti (ciltacabtagene autoleucel) Receives the EC’s Approval for the Treatment of Relapsed and Refractory Multiple Myeloma

Published: May 26, 2022 | Tags: Legend, Carvykti, ciltacabtagene autoleucel, EU, Relapsed and Refractory Multiple Myeloma

GrowLab Reports Results of Comacadine for the Treatment of Diabetes Mellitus

Published: May 26, 2022 | Tags: GrowLab, Comacadine, Diabetes Mellitus

Servier’s Tibsovo (ivosidenib) Receives the US FDA's Approval for the Treatment of IDH1-mutated Acute Myeloid Leukemia

Published: May 26, 2022 | Tags: Servier, Tibsovo, ivosidenib, US FDA, IDH1-mutated Acute Myeloid Leukemia

Targan Secures Funding from Mountain Group Partners and NovaQuest Capital Management to Commercialize Poultry Vaccination and Gender Identification System

Published: May 26, 2022 | Tags: Targan, Funding, Mountain Group Partners, NovaQuest Capital Management, Poultry Vaccination, Gender Identification System

KaliVir and Roche Enters into a Global Licensing Agreement to Discover, Develop and Commercialize Novel Oncolytic Vaccinia Viruses

Published: May 26, 2022 | Tags: KaliVir, Roche, Global Licensing Agreement, Novel Oncolytic Vaccinia Viruses, VET Platform

Aeterna Zentaris and Consilient Health Launches Ghryvelin (macimorelin) Across the EU for the Diagnosis of Adult Growth Hormone Deficiency

Published: May 26, 2022 | Tags: Ghryvelin, macimorelin, Aeterna, Consilient Health, Novo Nordisk, Europe, Adult Growth Hormone Deficiency

PharmaTher Entered into a Development Agreement with CCBIO to Develop and Commercialize Wearable Ketamine Delivery Device

Published: May 25, 2022 | Tags: PharmaTher, CCBIO, Wearable Ketamine Delivery Device

Endotronix Presents Results of Cordella PA Pressure Sensor System in (SIRONA 2) for NYHA Class III Heart Failure at ESC 2022

Published: May 25, 2022 | Tags: Endotronix, Cordella PA Pressure Sensor System, SIRONA 2, NYHA Class III Heart Failure, ESC, 2022

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) to Treat IBD at DDW 2022

Published: May 25, 2022 | Tags: Janssen, Tremfya, guselkumab, P-II, GALAXI 1 Trial, Stelara, ustekinumab, IBD, DDW, 2022

Junshi Biosciences Reports Results of VV116 (JT001) in the P-III Registrational Trial for Early Treatment of COVID-19 in High Risk Patients

Published: May 25, 2022 | Tags: Junshi Biosciences, VV116, JT001, P-III, Registrational Trial, COVID-19

Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerative Colitis at DDW 2022

Published: May 25, 2022 | Tags: Everest, Pfizer, Etrasimod, P-III, ELEVATE UC 12, 52, Studies, Ulcerative Colitis, DDW, 2022

CASI Entered into a Sublicense Agreement with Tianshi for CID-103 to Treat Autoimmune Diseases

Published: May 25, 2022 | Tags: CASI, Sublicense Agreement, Tianshi, CID-103, Autoimmune Diseases

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

Published: May 24, 2022 | Tags: Ocugen, NeoCart, US FDA, Regenerative Medicine Advanced Therapy, RMAT, Knee Injury, Lesions, Knee Cartilage

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)

Published: May 24, 2022 | Tags: UCB, Bimekizumab, P-III, BE MOBILE 1, BE MOBILE 2, Axial Spondyloarthritis, Ankylosing Spondylitis

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis

Published: May 24, 2022 | Tags: Lilly, Clinical Remission, Mirikizumab, P-III, LUCENT-2, Ulcerative Colitis

ImmuntyBio Submits Biologics License Application for N-803 + BCG to Treat BCG-unresponsive NMIBC CIS

Published: May 24, 2022 | Tags: ImmuntyBio, Biologics License Application, N-803, BCG, BCG-unresponsive NMIBC CIS, Bladder Cancer

Janssen Publishes the Results of Two Studies with Xarelto (rivaroxaban) + Aspirin (Acetylsalicylic Acid) in Patients with CAD and/or PAD

Published: May 24, 2022 | Tags: Bayer, Janssen, Xarelto, rivaroxaban, Aspirin, Acetylsalicylic Acid, CAD, PAD

Innoviva Entered into a Definitive Merger Agreement with Entasis Therapeutics

Published: May 24, 2022 | Tags: Innoviva, Entasis Therapeutics, SUL-DUR, Merger, Acquisition, Infectious Disease

Alnylam Presents 18-Month Results in the P-III (HELIOS-A) Study of Vutrisiran for hATTR Amyloidosis with Polyneuropathy at ESC 2022

Published: May 23, 2022 | Tags: Alnylam, Exploratory Cardiac Endpoints, P-III, HELIOS-A Study, Vutrisiran, hATTR, Amyloidosis, Polyneuropathy, ESC, 2022

Merck Receives CHMP Positive Opinion of Keytruda (pembrolizumab) as Adjuvant Treatment for Stage IIB or IIC Melanoma

Published: May 23, 2022 | Tags: Merck, CHMP, Keytruda, pembrolizumab, Stage IIB, IIC, Melanoma

Regeneron Presents Results of Evkeeza (evinacumab) in P-III Trial for Homozygous Familial Hypercholesterolemia in Children at EAS 2022

Published: May 23, 2022 | Tags: Regeneron, Evkeeza, evinacumab, P-III Trial, Homozygous Familial Hypercholesterolemia, EAS, 2022

Kala Entered into Definitive Agreement with Alcon to Acquire Eysuvis and Inveltys for the Treatment of Acute Dry Eye Disease

Published: May 23, 2022 | Tags: Kala, Alcon, Acquire, Eysuvis, Inveltys, Acute Dry Eye Disease

Eli Lilly and Incyte Receive CHMP Positive Opinion of Olumiant (baricitinib) for the Treatment of Adults with Severe Alopecia Areata

Published: May 23, 2022 | Tags: Eli Lilly, Incyte, CHMP, Olumiant, baricitinib, Alopecia Areata

Bridgebio and Affiliate Phoenix Tissue Repair Presents Results of PTR-01 in P-II Trial for Recessive Dystrophic Epidermolysis Bullosa at SID 2022

Published: May 23, 2022 | Tags: Bridgebio Pharma, PTR-01, P-II Trial, Recessive Dystrophic Epidermolysis Bullosa, SID, 2022

Related Post: PharmaShots Weekly Snapshots (May 16 - 20, 2022)